Added to YB: 2025-10-21
Pitch date: 2025-10-18
HROW [neutral]
Harrow, Inc.
-13.69%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$40.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Harrow Investor Day Summary
HROW (update): Ophthalmic specialty pharma targeting >$1B revenue by 2027 vs $199.6M in 2024. MELT-300 Phase 3 promising (65% vs 36% sedation), FDA SPA approved, NDA mid-2027. TRIESENCE $37M revenue, VEVYE captured 7.8% dry eye market. Pipeline NDAs 2027-28, debt refinanced saving $3M annually, $90M liquidity available.
Read full article (5 min)